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Abstract
Luteinizing hormone-releasing hormone (LHRH) is the key hormone in the control of reproductive
functions. In recent years, it has become evident that LHRH might act as a growth modulatory factor
in tumors of the reproductive system. We have shown that in prostate cancer cells LHRH is
expressed, together with its receptors, to negatively regulate cell proliferation. In these cells, LHRH
acts as an antimitogenic factor through the activation of the Gi-cAMP intracellular signaling pathway.
More recently, we investigated whether an LHRH-based autocrine system might also be expressed
in tumors that are not classically related to the reproductive tract, such as melanoma. Malignant
melanoma is known to be characterized not only by a high proliferation rate, but also by an aggressive
metastatic behavior. We have demonstrated that both LHRH and LHRH receptors are expressed in
human melanoma cells (BLM and Me15392). Activation of LHRH receptors by means of a potent
LHRH agonist (Zoladex) signiﬁcantly inhibited cell proliferation. The LHRH agonist also reduced the
ability of melanoma cells to invade a reconstituted basement membrane (Matrigel) and to migrate in
response to a chemotactic stimulus. These data indicate that: (a) in prostate cancer cells the LHRH
receptor is coupled to a Gi-cAMP signal transduction pathway; (b) LHRH and LHRH receptors are
also expressed in tumors that are not classically related to the reproductive system, such as
melanoma; in melanoma cells, LHRH might act as an inhibitory factor on both cell proliferation and
metastatic behavior. It is suggested that, in melanoma, LHRH receptors might represent a diagnostic
marker and a possible molecular target for new therapeutic approaches for this pathology.
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Introduction
Luteinizing hormone-releasing hormone (LHRH) is the
hypophysiotropic decapeptide synthesized in the hypothala-
mus that plays a crucial role in the control of reproductive
functions (Fink 1988, Shupnik 1996). The human LHRH
gene, which is organized into four exons and three introns,
is located on chromosome 8 (Fernald & White 1999). The
peptide is synthesized in neurons of the hypothalamus as a
pre-pro-hormone before being processed to the mature hor-
mone which is then released into the portal system of the
median eminence. Through the portal vessels, the hormone
reaches the anterior pituitary where it binds to speciﬁc recep-
tors on the gonadotropes to regulate gonadotropin synthesis
and secretion (Fink 1988, Shupnik 1996). LHRH and the two
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gonadotropins (luteinizing hormone, LH; follicle stimulating
hormone, FSH) are secreted in a pulsatile way, and this pul-
satility is crucial for the maintenance of the functions of the
pituitary–gonadal axis (Kalra 1993). Pulsatile administration
of LHRH in patients with hypothalamic dysfunctions has
been shown to induce a regular pattern of LH and FSH
secretion, thus restoring the fertility capacity (Conn &
Crowley 1994, Schally 1994). On the other hand, chronic
applications of LHRH or LHRH analogs lead to a complete
suppression of reproductive function, due to LHRH receptor
down-regulation and desensitization (Schally 1994,
Stojilkovic & Catt 1995). This mechanism of action rep-
resents the molecular basis for the treatment of hormone-
dependent pathologies such as breast and prostate cancer
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(Crawford et al. 1995, Lippman 1998, Green & Furr 1999,
Manni 1999).
The pituitary LHRH receptor has been cloned and char-
acterized (Kakar et al. 1992). In humans, its gene is located
on chromosome 4 and is organized into three exons and two
introns (Kakar et al. 1992). This gene encodes a 328 amino
acid protein belonging to the superfamily of seven transmem-
brane domain receptors (Kakar et al. 1992, Stojilkovic et al.
1994). The series of events that follows the binding of the
neurohormone to its receptor has been widely investigated.
It is now clear that the pituitary LHRH receptor is coupled
to a Gq/11 protein (Naor et al. 1998, Kraus et al. 2001).
Phospholipase (PL) Cβ is the primary effector in the intracel-
lular cascade of events triggered by LHRH; the generated
second messengers inositol trisphosphate and diacylglycerol
lead to the activation of protein kinase C and to the mobiliz-
ation of intracellular pools of Ca2+ (Naor et al. 1998). LHRH
also activates PLA2, PLD, and the MAP kinase cascade,
which provides an important link for the transmission of sig-
nals from the cell surface to the nucleus and plays a role in
the regulation of gonadotropin transcription (Naor et al.
1998, Kraus et al. 2001).
Recently, a gene coding for a second form of LHRH
(which is called LHRH-II) has been identiﬁed in several pla-
cental mammals, including humans (White et al. 1998). The
LHRH-II peptide is identiﬁed as [His5-Trp7-Tyr8]-LHRH,
indicating that the amino acid sequence presents three substi-
tutions in these three positions. LHRH-II is mainly present
in the midbrain, but it is also widely expressed in peripheral
tissues such as prostate, bone marrow, and kidney (White et
al. 1998).
The demonstration of the presence of two forms of
LHRH suggests speciﬁc functions for each peptide. This
observation prompted different authors to investigate the pos-
sible existence of multiple LHRH receptors. These studies
led to the identiﬁcation of an LHRH-type II receptor in mon-
keys. This receptor is 96% identical with a putative human
LHRH-type II receptor, which is composed of 379 amino
acids (Neill 2002). The functions of LHRH-II and its putative
receptor are still under investigation (White et al. 1998, Neill
2002).
LHRH in prostate cancer
LHRH and LHRH receptors have been reported to be
expressed also in some peripheral tissues, particularly in
those related to the endocrine system. In our laboratory we
investigated whether LHRH and LHRH receptors might be
present in prostate cancer, and whether they might be
involved in the control of tumor growth. These studies have
been performed in either androgen-dependent (LNCaP) or
androgen-independent (DU 145) human prostate cancer cell
lines.
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By RT-PCR we have shown ﬁrst that the mRNA for
LHRH is expressed in both LNCaP and DU 145 cells
(Limonta et al. 1993, Dondi et al. 1994). In these cell lines
we have also demonstrated the presence of the mRNA coding
for the LHRH receptor, which appeared to be identical in its
sequence to that found in the pituitary (Dondi et al. 1994).
By Western blot analysis and by using a speciﬁc monoclonal
antibody raised against the human pituitary receptor
(Karande et al. 1995), we have further been able to demon-
strate that a protein band of approximately 64 kDa is present
in membrane preparations of prostate cancer cells. This
molecular weight corresponds to that previously reported for
the LHRH receptor at the pituitary level in humans (Karande
et al. 1995).
Taken together, these data demonstrated that an LHRH-
based system is expressed in prostate cancer, which might
participate in the local regulation of tumor growth. This
hypothesis has been conﬁrmed by showing that the activation
of locally expressed LHRH receptors by means of potent
LHRH superagonists signiﬁcantly reduces the proliferation
of prostate cancer cells both in vitro (Limonta et al. 1992,
Dondi et al. 1994) and in vivo (Dondi et al. 1998).
On the basis of these results we have concluded that, in
either androgen-dependent or androgen-independent prostate
cancer, the local LHRH system might act as a paracrine/
autocrine negative regulator of tumor growth. These observa-
tions are in agreement with those reported for tumors of the
female reproductive tract, such as breast (Keri et al. 1991,
Kakar et al. 1994, Kottler et al. 1997), endometrial (Imai et
al. 1994, Chatzaki et al. 1996), and ovarian (Yin et al. 1998,
Emons et al. 2000) cancer.
These data seem to suggest that, when utilized for the
treatment of hormone-related tumors, LHRH agonists might
also exert a direct inhibitory action at the level of the tumor
tissue. Moreover, LHRH analogs should be considered for a
possible treatment of prostate cancer, in its androgen-
independent stage.
Mechanism of action of LHRH
At the pituitary level, LHRH receptors mediate the stimula-
tory action of the neuropeptide on gonadotropin synthesis
and secretion. As mentioned in the Introduction, these recep-
tors are coupled to the Gq-PLC signal transduction pathway.
In cancer cells and tissues, activation of LHRH receptors
brings about a signiﬁcant inhibition of cell proliferation.
Therefore, we hypothesized that the signal transduction path-
way coupled to the LHRH receptor in prostate cancer might
be different to that described for the pituitary receptor.
In preliminary experiments, we observed that the treat-
ment of prostate cancer cells, either androgen-dependent or
androgen-independent, with LHRH agonists does not affect
phosphoinositide turnover or intracellular Ca2+ levels (RM
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observations). This suggested to us that, in these cells, LHRH
receptors might not be coupled to the Gq/11-PLC system.
Therefore, we considered that the antiproliferative action of
LHRH agonists might be mediated by the Gi-cAMP signal
transduction pathway. It is well known that pertussis toxin
(PTX), through ADP-ribosylation of Gi proteins, impairs the
receptor–effector interaction in this pathway (Ui & Katada
1990). Therefore, we investigated whether PTX might inter-
fere with the antimitogenic action of a potent LHRH agonist
(LHRH-A; Zoladex (AstraZeneca)). As expected, LHRH-A
signiﬁcantly inhibited prostate cancer cell growth; the anti-
proliferative action of the LHRH agonist was completely pre-
vented by PTX, thus suggesting that the receptor might be
coupled to a Gi protein. To verify this hypothesis, we ana-
lyzed whether LHRH-A might affect PTX-induced ADP-
ribosylation of this protein. Incubation of prostate cancer cell
membranes with PTX, in the presence of 32P-NAD, brought
about ADP-ribosylation of a 41-kDa Gi protein. LHRH-A
substantially counteracted the transfer of 32P-ADP-ribose to
this protein. To deﬁnitely conﬁrm that in prostate cancer cells
LHRH receptors might be coupled to Gi proteins, we studied
the effects of LHRH-A on forskolin-induced cAMP accumu-
lation; it is actually well known that the Gi subunit is nega-
tively correlated with cAMP production. We found that, in
tumor cells, LHRH-A did not affect cAMP levels when given
alone. However, the LHRH analog completely counteracted
the increase in cAMP levels induced by forskolin.
Taken together, these results indicate that, in prostate
cancer cells, the LHRH receptor is linked to a Gi protein
which, through inhibition of cAMP accumulation, may
mediate the antiproliferative action of the peptide. These
observations are in line with those reported for the LHRH
receptor in ovarian and endometrial carcinoma (Imai et al.
1996, Imai & Tamaya 2000).
The molecular mechanisms which follow Gi activation
to lead to the inhibition of cancer cell proliferation are still
poorly understood. In previous studies, we have reported that
LHRH agonists counteract the mitogenic stimuli of growth
factors, such as epidermal growth factor or insulin-like
growth factor (Moretti et al. 1996, Montagnani Marelli et al.
1999). These LHRH agonists seem to interfere with some of
the intracellular events activated by the growth factors, such
as receptor expression or receptor tyrosine phosphorylation
(Moretti et al. 1996, Montagnani Marelli et al. 1999). It is
then possible that, after the activation of the Gi protein, the
reduced levels of cAMP might directly affect the intracellular
mechanisms which mediate mitogenic stimuli in cancer cells
(Fig. 1).
LHRH in melanoma
In a recent paper, it has been reported that LHRH binding
sites are present in glioblastoma biopsies and it has been sug-
gested that they might represent a diagnostic marker, and
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Figure 1 Schematic representation of the suggested
intracellular transduction pathway linked to the LHRH
receptor in tumor cells. GFs, growth factors.
possibly a new therapeutic target, for nervous system tumors
(van Groeninghen et al. 1998). Since both glial cells and
melanocytes share the same neuroectodermal origin, we rea-
soned that an LHRH-based system (LHRH and LHRH
receptors) might also be expressed in melanoma cells.
Cutaneous melanoma is a tumor known for its uncontrol-
lable growth and for its ability to give rise to metastases
(MacKie 1998). The incidence of this tumor is increasing
dramatically (Parkin et al. 1999) and although its prognosis
has improved in the last decades particularly due to early
diagnosis, this remains very poor in advanced cases when
tumor cells acquire a strong potential to disseminate metast-
ases (MacKie 1998). Moreover, advanced melanoma is a
multistep process, which starts from the initial transformation
of melanocytes, then goes through a radial growth phase, to
eventually progress to the vertical growth phase
(Lazar-Molnar et al. 2000). It is particularly in this phase
that tumor cells start giving rise to metastases (Shih & Herlyn
1993).
The molecular mechanisms that are involved in the
growth and progression of melanoma are still poorly under-
stood. The experiments here described have been performed
to clarify whether an LHRH-based system (LHRH and the
respecitve receptors) is expressed in melanoma cells. We
have also investigated whether the activation of this system
might affect the proliferative rate as well as the metastatic
properties of this tumor. For these studies we utilized two
human melanoma cell lines: BLM and Me15392 (kindly
provided by Dr Van Muijen, Department of Pathology,
University Hospital, Nijmegen, The Netherlands and by Dr
Parmiani, Istituto Nazionale per lo Studio e la Cura dei
Tumori, Milano, Italy respectively). LHRH receptor acti-
vation has been achieved by using the potent LHRH-A
Zoladex.
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Table 1 Characteristics of 125I-LHRH-A binding to human melanoma cell membranes
Dissociation constant (Kd) 125I-LHRH-A binding capacity
(nM) (fmoles/mg protein)
BLM cells 0.7–1.1 150–200
Me15392 cells 0.1–0.6 200–250
Rat pituitaries 1.5–2.0 70–100
Expression of LHRH and LHRH receptors
The expression of both LHRH and LHRH receptors in mela-
noma cells has been investigated by RT-PCR, as described
above for the studies performed in prostate cancer cells. With
regard to the expression of LHRH, according to the sequence
of the oligonucleotide primers used, the predicted fragment
of 228 bp was observed in both BLM and Me15392 cells.
After Southern blotting, the cDNA fragments hybridized
with the 32P-labeled oligonucleotide probe speciﬁc for the
LHRH cDNA (Oikawa et al. 1990). In the case of the expres-
sion of the LHRH receptor mRNA, the results obtained dem-
onstrate that the predicted 885-bp cDNA fragment is present
both in BLM and in Me15392 cells; this band hybridized
with the 32P-labeled probe speciﬁc for the LHRH receptor
cDNA (Kakar et al. 1994). The presence of LHRH receptors
in melanoma cells has been further investigated at the protein
level by Western blot and by using the speciﬁc F1G4 anti-
body raised against the human pituitary receptor (Karande et
al. 1995). The results obtained demonstrate that a protein of
approximately 64 kDa molecular mass is present in mem-
brane preparations from both BLM and Me15392 cells. This
molecular weight corresponds to that previously reported for
the human pituitary receptor (Wormald et al. 1985). Finally,
Figure 2 Effects of the LHRH agonist (LHRH-A) Zoladex on the invasive (Matrigel assay) and on the migratory
(Chemomigration assay) properties of melanoma cells. *P < 0.05 compared with Controls.
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LHRH receptors in melanoma cells have been analyzed also
in terms of binding parameters. Radioreceptor assays have
been performed using 125I-LHRH-A as the speciﬁc ligand
(Limonta et al. 1992, Dondi et al. 1994). The assays demon-
strated that binding sites for 125I-LHRH-A are present on the
membranes of both BLM and Me15392 cells. Computer ana-
lysis of the data obtained from displacement curves indicated
the presence of a single class of high afﬁnity binding sites
(Kd in the nM range) in both melanoma cell lines, as well as
in rat pituitaries used as controls (Table 1).
So far, divergent results have been reported for the bind-
ing characteristics of LHRH receptors in cancers related to
the reproductive tract (Limonta et al. 1992, Emons et al.
1993, Dondi et al. 1994, Emons & Schally 1994, Imai et al.
1994). The data here described indicate that, in melanoma
cells, LHRH receptors can bind LHRH analogs with a high
afﬁnity.
Antiproliferative activity of LHRH
The observation that both LHRH and LHRH receptors are
expressed in melanoma cells prompted us to investigate the
possible role played by this LHRH-based system in the
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control of melanoma growth. Melanoma cells have been
treated daily, for 7 days, with LHRH-A (10−11–10−6 M). The
treatment resulted in a signiﬁcant and dose-dependent inhi-
bition of cell proliferation, with an EC50 dose in the nM
range. This antimitogenic activity was found to be speciﬁc
since it was completely counteracted by the simultaneous
treatment of the cells with an LHRH antagonist (Antide).
As in the case of other tumors, the development of mela-
noma has been found to be related to a decreased dependency
on external mitogenic stimuli (Halaban 1996) as well as to
an increased expression of locally produced growth factors
(Lu & Kerbel 1994, Shih & Herlyn 1994). The data here
reported indicate that, in addition to stimulatory growth fac-
tors, melanoma cells might express an LHRH-based inhibi-
tory system. Activation of this system by means of LHRH
agonists may reduce tumor growth, possibly by interfering
with the remaining positive effect of the mitogenic stimuli.
Antimetastatic activity of LHRH
Experiments have been performed to verify whether the acti-
vation of locally expressed LHRH receptors might also affect
the metastatic behavior of melanoma cells. In a ﬁrst series of
experiments, we evaluated the effects of LHRH-A on the
ability of BLM cells to migrate towards a chemoattractant
(fetal bovine serum 5%), using the Boyden’s chamber tech-
nique. We found that treatment of BLM cells with LHRH-A
Figure 3 Schematic representation of the antiproliferative and antimetastatic properties of LHRH in tumor cells.
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(10−6 M for 5 days) signiﬁcantly reduced the ability of the
cells to migrate in response to the chemoattractant (Fig. 2).
We then analyzed the effects of LHRH-A (10−6 M) on the
ability of melanoma cells to invade a reconstituted basement
membrane (Matrigel). BLM cells spontaneously form cell
aggregates in Matrigel when prepared by the hanging-drop
technique. For these experiments, the aggregates in Matrigel
were covered with culture medium in the absence or in the
presence of LHRH-A (10−6 M) for 4, 8, or 12 days. The
results obtained show that BLM cells actively leave the
aggregate by degrading the Matrigel preparation. The treat-
ment of the cells with LHRH-A completely counteracted the
migration of the cells at all the time intervals considered.
Taken together, these data indicate that the activation of
locally expressed LHRH receptors signiﬁcantly reduces the
ability of melanoma cells to migrate in response to a chemo-
tactic stimulus and to degrade extracellular matrix compo-
nents. To the authors’ knowledge, this is the ﬁrst report of a
possible antimetastatic activity of LHRH in tumors. Prelimi-
nary data obtained in our laboratory seem to indicate that
LHRH exerts this antimetastatic activity by reducing the
expression of cell adhesion molecules (integrins) as well as
the expression and the activity of enzymes able to degrade
the extracellular matrix (matrix metalloproteinases, MMPs).
Both integrins and MMPs have been shown to play a crucial
role in the molecular mechanisms leading to melanoma pro-
gression (Natali et al. 1993, Hofmann et al. 2000).
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As pointed out above, the clinical options for advanced
melanoma are still limited, due to the intrinsic resistance of
the tumor to standard chemotherapy, but also to its ability to
give rise to metastases (Meyer & Hart 1998). The data here
reported seem to suggest that LHRH agonists might reduce
not only the proliferation rate, but also the metastatic poten-
tial of melanoma cells (see Fig. 3).
The intracellular signaling pathways that are triggered
after the activation of LHRH receptors in melanoma cells are
still unclear. In preliminary experiments, we have observed
that LHRH-A does not affect forskolin-induced cAMP levels
in BLM cells (RM Moretti, M Montagnani Marelli & P
Limonta, unpublished observations). This seems to suggest
that the intracellular signaling pathway coupled to the LHRH
receptor in melanoma is different from that found in prostate
cancer. Experiments are in progress in our laboratory to clar-
ify this issue.
Conclusions
LHRH is expressed, together with its receptors, in hormone-
related tumors such as prostate cancer, to act as a local autoc-
rine/paracrine growth inhibitory factor. In prostate cancer
cells, the LHRH receptor is coupled to the Gi-cAMP pathway
to inhibit cell proliferation. This is at variance with the
LHRH receptor at the pituitary level which is coupled to the
Gq-PLC pathway to stimulate gonadotropin synthesis and
secretion.
LHRH and LHRH receptors are expressed also in tumors
that are not classically related to the endocrine system, such
as melanoma. In melanoma cells, the locally expressed
LHRH-based system negatively regulates the proliferation of
the cells as well as their ability to migrate towards chemotac-
tic stimuli and to invade a reconstituted basement membrane.
Therefore, in melanoma, the activation of LHRH receptors
might reduce not only tumor growth but also its metastatic
potential. Moreover, the LHRH receptor might represent a
new diagnostic (and possibly prognostic) marker for the
detection of skin tumors.
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